AU2002333134A1 - Montelukast granule formulation - Google Patents
Montelukast granule formulationInfo
- Publication number
- AU2002333134A1 AU2002333134A1 AU2002333134A AU2002333134A AU2002333134A1 AU 2002333134 A1 AU2002333134 A1 AU 2002333134A1 AU 2002333134 A AU2002333134 A AU 2002333134A AU 2002333134 A AU2002333134 A AU 2002333134A AU 2002333134 A1 AU2002333134 A1 AU 2002333134A1
- Authority
- AU
- Australia
- Prior art keywords
- granules
- composition
- montelukast sodium
- dose
- montelukast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
TITLE OF THE INVENTION
MONTELUKAST GRANULE FORMULATION
BACKGROUND OF THE INVENTION Montelukast sodium (SINGULAIR®) is a leukotriene receptor antagonist approved for the treatment of asthma in adults and pediatric patients from 2 years old. The drug is currently being studied for the treatment of seasonal allergic rhinitis, as well as for potential use in children as young as 6 months old. Montelukast sodium is currently available as 10 mg film-coated tablets for adults and 4 mg and 5 mg chewable tablets for children.
SUMMARY OF THE INVENTION
The present invention relates to a novel formulation of montelukast sodium in the form of granular powder which may be ingested directly or mixed with food or other comestibles. The novel formulation is suitable for use by patients who either have difficulty swallowing or chewing tablets or who prefer not to do so.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a flowable and dispersible pharmaceu- tical composition which comprises granules having a substrate coated with montelukast sodium, and a lubricant. The granules of the present composition may be prepared by coating the substrate, optionally first agglomerated with a pharmaceutically acceptable binder, with an aqueous solution of montelukast sodium. The resulting drug granules are dried, and blended with a pharmaceutically acceptable lubricant to produce a flowable and dispersible composition suitable for packaging. In the present invention, the substrate may be any that is pharmaceutically acceptable; typically a sugar such as mannitol, sucrose, lactose, xylitol or the like is used. The substrate is preferably used in a form that is free-flowing, a characteristic that facilitates accurate dosing of the final product granules into unit- dose pouches for market distribution. If the substrate is not free-flowing, it is necessary to agglomerate individual particles into larger granules.
In one embodiment of the granules, the substrate is spray-dried mannitol, which may be prepared by spray-drying an aqueous solution of mannitol using conventional processes. Commercially available spray-dried mannitol (e.g. PEARLITOL® SD 200, Roquette Freres, France) may also be used in the present invention. Individual particles of spray-dried mannitol such as PEARLITOL® SD
200 are generally spherical which imparts to this material its free-flowing property. Mannitol is preferably used because of its sweet, cooling taste and non-hygroscopic nature. The substrate typically comprises from about 95 to about 98% weight of the composition. In cases where the substrate is very free-flowing on its own it may be used in producing the drug granules without further agglomeration; or optionally, the substrate may be first agglomerated with a pharmaceutically acceptable binder. Suitable pharmaceutically acceptable binders are for example hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose and poly- vinylpyrrolidone. The agglomeration of the substrate particles is carried out by applying an aqueous solution of the binder onto the substrate, for example by spraying a solution of the binder onto a fluidized bed of the substrate. The binder, when used, typically comprises from about 2 to about 5% of the composition. The resultant agglomerated substrate particles are dried and used in the next step. The substrate particles are coated with montelukast sodium by, for example, spraying an aqueous drug solution directly on to a fluidized bed of the substrate to produce the drug granules. The granulation process results in drug coated granules, which after drying are sized to provide granules of less than about 850 microns. The sized granules are blended with a lubricant and used to fill the final product container.
Montelukast sodium is a known compound and its preparation is disclosed in, for example, US Patents 5,565,473 and 5,614,632. For use in the present invention a solution of montelukast sodium in water is used in the granulation process. Montelukast typically comprises from about 0.4% to about 5% of the composition such that each unit dose package would contain the desired amount of montelukast sodium, ranging from about 2 mg to about 20 mg per dose.
One of skill in the art will appreciate that other inert ingredients may be added to the composition to impart to the final product desired properties such as taste or appearance; for example, sweetners such as aspartame, flavoring compounds, and food colorings may be added.
The dried and sized drug granules are tumble blended with a lubricant to facilitate product flow during unit dosage form filling operation, and to prevent binding of moving metal components during such operation. Suitable lubricants are pharmaceutically acceptable and include, without limitation, magnesium stearate, talc,
and the like. The lubricant typically comprises from about 0.25 to about 1% of the composition.
The lubricated granules are used to fill the final unit dosage package, which must provide light and moisture protection for the drug granules. One example of suitable packaging is foil (for example aluminum) pouch or sachet. The foil may be laminated with an outer polyester film that acts as a child-resistant (biting and tearing) barrier. An inner linear low-density polyethylene laminate acts as the heat seal component for the pouches.
Montelukast sodium is a leukotriene receptor antagonist and as such may be used for the treatment and prevention of leukotriene-mediated diseases and disorders. Leukotriene antagonists are useful in the treatment of asthma, allergic rhinitis (including seasonal and perennial), atopic dermatitis, chronic urticaria, sinusitis, nasal polyps, chronic obstructive pulmonary disease, conjunctivitis including rhinoconjunctivitis, migraine, cystic fibrosis, and wheezing secondary to viral (such as respiratory syncytial virus) bronchiolitis, among others.
For the treatment of asthma, the present composition may be administered to patients by either direct placement in the mouth of the patient, or by pre-'mixing with a soft food such as applesauce and the like. The established dose of montelukast for asthma is typically about 10 mg per day for an adult, and for children from about 2 to about 5 mg per day. The magnitude of the dose may, however, vary with the nature and the severity of the condition to be treated, and the age, weight and response of the individual patient; a physician of ordinary skill in the art will be able to adjust the typical dose upward or downward to devise a suitable dose and dosing schedule based on the individual characteristics and need of the patient. For the treatment of allergic rhinitis (including seasonal and perennial), the present composition may be administered to patients by either direct placement in the mouth of the patient, or by pre-mixing with food such as applesauce and the like. The dose of montelukast for allergic rhinitis is about 10 mg per day for an adult, and for children from about 2 to about 5 mg per day. The magnitude of the dose may, however, vary with the nature and the severity of the condition to be treated, and the age, weight and response of the individual patient; a physician of ordinary skill in the art will be able to adjust the typical dose upward or downward to devise a suitable dose and dosing schedule based on the individual characteristics and need of the patient.
For the treatment of atopic dermatitis, the present composition may be administered to patients by either direct placement in the mouth of the patient, or by pre-mixing with food such as applesauce and the like. The dose of montelukast for atopic dermatitis may be about 10 mg per day for an adult, and for children from about 2 to about 5 mg per day. The magnitude of the dose may, however, vary with the nature and the severity of the condition to be treated, and the age, weight and response of the individual patient; a physician of ordinary skill in the art will be able to adjust the typical dose upward or downward to devise a suitable dose and dosing schedule based on the individual characteristics and need of the patient. For the treatment of chronic urticaria, the present composition may be administered to patients by either direct placement in the mouth of the patient, or by pre-mixing with food such as applesauce and the like. The dose of montelukast for chronic urticaria may be about 10 mg per day for an adult, and for children from about 2 to about 5 mg per day. The magnitude of the dose may, however, vary with the nature and the severity of the condition to be treated, and the age, weight and response of the individual patient; a physician of ordinary skill in the art will be able to adjust the typical dose upward or downward to devise a suitable dose and dosing schedule basβd on the individual characteristics and need of the patient.
For the treatment of sinusitis, the present composition may be administered to patients by either direct placement in the mouth of the patient, or by pre-mixing with soft food such as applesauce and the like. The dose of montelukast for sinusitis may be about 10 mg per day for an adult, and for children from about 2 to about 5 mg per day. The magnitude of the dose may, however, vary with the nature and the severity of the condition to be treated, and the age, weight and response of the individual patient; a physician of ordinary skill in the art will be able to adjust the typical dose upward or downward to devise a suitable dose and dosing schedule based on the individual characteristics and need of the patient.
For the treatment of nasal polyps, the present composition may be administered to patients by either direct placement in the mouth of the patient, or by pre-mixing with food such as applesauce and the like. The dose of montelukast for nasal polyps may be about 10 mg per day for an adult, and for children from about 2 to about 5 mg per day. The magnitude of the dose may, however, vary with the nature and the severity of the condition to be treated, and the age, weight and response of the individual patient; a physician of ordinary skill in the art will be able to adjust the
typical dose upward or downward to devise a suitable dose and dosing schedule based on the individual characteristics and need of the patient.
For the treatment of chronic obstructive pulmonary disease (COPD), the present composition may be administered to patients by either direct placement in the mouth of the patient, or by pre-mixing with soft food such as applesauce and the like. The dose of montelukast for COPD may be about 10 mg per day for an adult, and for children from about 2 to about 5 mg per day. The magnitude of the dose may, however, vary with the nature and the severity of the condition to be treated, and the age, weight and response of the individual patient; a physician of ordinary skill in the art will be able to adjust the typical dose upward or downward to devise a suitable dose and dosing schedule based on the individual characteristics and need of the patient.
For the treatment of conjunctivitis (including rhinoconjunctivitis), the present composition may be administered to patients by either direct placement in the mouth of the patient, or by pre-mixing with food such as applesauce and the like. The dose of montelukast for conjunctivitis may be about 10 mg per day for an adult, and for children from about 2 to about 5 mg per day. The magnitude of the dose may, however, vary with the nature and the severity of the condition to be treated, and the age, weight and response of the individual patient; a physician of ordinary skill in the art will be able to adjust the typical dose upward or downward to devise a suitable dose and dosing schedule based on the individual characteristics and need of the patient.
For the treatment of cystic fibrosis, the present composition may be administered to patients by either direct placement in the mouth of the patient, or by pre-mixing with food such as applesauce and the like. The dose of montelukast for cystic fibrosis may be about 10 mg per day for an adult, and for children from about 2 to about 5 mg per day. The magnitude of the dose may, however, vary with the nature and the severity of the condition to be treated, and the age, weight and response of the individual patient; a physician of ordinary skill in the art will be able to adjust the typical dose upward or downward to devise a suitable dose and dosing schedule based on the individual characteristics and need of the patient.
For the treatment of wheezy kid syndrome, or wheezing secondary to viral (such as respiratory syncytial virus) bronchiolitis, the present composition may be administered to patients by either direct placement in the mouth of the patient, or by pre-mixing with food such as applesauce and the like. The dose of montelukast for
these conditions may be about 10 mg per day for an adult, and for children from about 2 to about 5 mg per day. The magnitude of the dose may, however, vary with the nature and the severity of the condition to be treated, and the age, weight and response of the individual patient; a physician of ordinary skill in the art will be able to adjust the typical dose upward or downward to devise a suitable dose and dosing schedule based on the individual characteristics and need of the patient.
The following description of the preparation of the present pharmaceutical composition is by way of example only, and not to be construed as limiting the scope of the invention in any manner. For the preparation of the drug granules, typically the substrate is charged into a fluid-bed granulator equipped with a top-spray nozzle. An aqueous solution of the binder is sprayed onto the fluidized substrate at a specified rate to form granules. The granules are dried and the dried granules are sprayed with an aqueous solution of montelukast sodium. The result drug granules are dried, and the dried granules are sized to <850 microns and then blended with a lubricant by tumble blending. The lubricated granules are re-blended prior to filling into pouches.
EXAMPLE 1 Preparation Of Montelukast Sodium Oral Granules
Granulation of Mannitol. Place into a suitably sized stainless steel container equipped with a high shear agitator: purified water USP (102 kg); while agitating at approximately 300 lpm add hydroxypropyl cellulose LF (HPC, 4.16 kg). Continue mixing at 300 rpm until hydroxypropyl cellulose is completely dissolved by visual inspection. Allow solution to defoam completely prior to use; use the binder solution within 72 hours of manufacture.
Transfer into a fluid bed granulator with a 670 L granulating bowl mannitol (Pearlitol SD 200, Roquette Freres, 194 kg), and spray onto the mannitol in the column the previously made HPC Solution (106 kg) using the following processing parameters:
Inlet Air Volume approx. 2500 scfm
Inlet Air Temperature approx. 68 deg C
Inlet Air Dewpoint approx. 12 deg C
Atomization Air Flow approx. 46 scfm Spray Rate approx. 1310 g/min
After solution delivery is complete, dry the product in the column to an endpoint of </= 0.5% LOD (loss on drying), using the following processing parameters:
Inlet Air Volume approx. 2500 scfm Inlet Air Temperature approx. 68 deg C
Inlet Air Dewpoint approx. 12 deg C
Atomization Air Flow approx. 30 scfm
Discharge the dried product into unlined stainless steel drums.
Drug Solution Preparation. Place into a suitably sized stainless steel container equipped with a high shear agitator purified water USP (49.0 kg, theoretical amount). While agitating at approximately 230 rpm add montelukast sodium (1.70 kg, theoretical amount). Continue mixing at 230 rpm until montelukast sodium is completely dissolved by visual inspection. Allow solution to defoam completely prior to use (use the drug solution within 24 hours of manufacture). The amount of drug solution prepared reflects a 2% excess of theoretical to account for spray drying. The amount of coating solution required may be adjusted if the coating efficiency of the process changes.
Drug Coating / Drying. Transfer into a fluid bed granulator with a 670 L granulating bowl the dried mannitol granules (198 kg, theoretical amount). Coat the granulation in the column with the montelukast solution (50.7 kg, theoretical amount) using the following processing parameters:
Inlet Air Volume approx. 2500 scfm Inlet Air Temperature approx. 68 deg C
Inlet Air Dewpoint approx. 12 deg C
Atomization Air Flow approx. 35 scfm
Spray Rate approx. 1310 g/min
After solution delivery is complete, dry the product in the column to an endpoint of < = 0.5% LOD, using the following processing parameters:
Inlet Air Volume approx. 2500 scfm
Inlet Air Temperature approx. 68 deg C
Inlet Air Dewpoint approx. 12 deg C
Atomization Air Flow approx. 25 scfm
After drying the dried granules (200 kg, theoretical amount) are sieved through a #20-mesh (approximately 850 micron) screen. Store granulation that passes through the 20 mesh (approximately 850 micron) screen in unlined stainless steel container(s) until lubrication The amount of drug solution listed reflects a 2.14% excess of theoretical to account for spray drying. The amount of coating solution required may be adjusted if the coating efficiency of the process changes. Additionally, the actual amount of drug solution sprayed may be adjusted based on the yield of dried mannitol granulation. The amount of drug solution listed above is the maximum amount that could be sprayed (assuming a 100% yield of mannitol granulation).
Lubrication Add to a 600 L bin the sieved granulation (200 kg, theoretical amount) and Magnesium Stearate (previously screened through a #30- mesh; approximately 600 micron screen, 0.500 kg). Blend the 600 L bin for 10 minutes at approximately 6 rpm. Discharge the lubricated blend into unlined stainless steel drums.
Re-blending Charge to a 600 L bin the lubricated granulation and blend the 600 L bin for 10 minutes at approximately 6 rpm. Store the re-blended granulation in the closed bin until sachet filling.
Sachet Filling Place the 600 L bin with re-blended granulation above the sachet filling line. Fill into foil sachets with a dual auger filler the re-blended granulation. Average Fill Weights: Target 0.500 g / sachet. The composition of Singulairτ Oral Granule 4 mg is shown below:
* equivalent to 4.0 mg montelukast free acid. ** removed during processing.
Claims (20)
1. Oral granules of montelukast sodium.
2. Oral granules of montelukast sodium comprising a pharmaceutically acceptable substrate coated with montelukast sodium.
3. Oral granules of montelukast sodium comprising a free-flowing pharmaceutically acceptable substrate coated with montelukast sodium.
Oral granules of Claim 2 wherein said substrate is spray-dried mannitol.
Oral granules of Claim 2 wherein said substrate is Peariitol SD 200.
6. Oral granules of Claim 4 wherein said substrate is spray-dried mannitol further agglomerated with a pharmaceutically acceptable binder.
7. Oral granules of Claim 6 wherein said binder is selected from hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, polyvinylpyrrolidone.
8. Oral granules of Claim 7 wherein said binder is hydroxypropyl cellullose.
9. A flowable and dispersible pharmaceutical composition which comprises granules comprising a pharmaceutically acceptable substrate coated with montelukast sodium, and a pharmaceutically acceptable lubricant.
10. A composition of Claim 9 wherein said granules comprise a free-flowing pharmaceutically acceptable substrate coated with montelukast sodium.
11. A composition of Claim 9 wherein said granules comprise spray-dried mannitol coated with montelukast sodium.
12. A composition of Claim 9 wherein said granules comprise Peariitol SD 200 coated with montelukast sodium.
13. A composition of Claim 9 wherein said granules comprise spray-dried mannitol further agglomerated with a pharmaceutically acceptable binder, and coated with montelukast sodium.
14. A composition of Claim 9 wherein said binder is selected from hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, polyvinylpyrrolidone.
15. A composition of Claim 14 wherein said binder is hydroxypropyl cellullose.
16. A compositon of Claim 9 wherein said lubricant is magnesium stearate or talc.
17. A composition of Claim 9 wherein said lubricant is magnesium stearate.
18. A compositon of Claim 11 wherein said lubricant is magnesium stearate.
19. A composition of Claim 12 wherein said lubricant is magnesium stearate.
20. A composition of Claim 13 wherein said lubricant is magnesium stearate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33954901P | 2001-10-26 | 2001-10-26 | |
| US60/339,549 | 2001-10-26 | ||
| PCT/CA2002/001604 WO2003035036A1 (en) | 2001-10-26 | 2002-10-22 | Montelukast granule formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002333134A1 true AU2002333134A1 (en) | 2003-07-03 |
| AU2002333134B2 AU2002333134B2 (en) | 2007-08-02 |
Family
ID=23329547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002333134A Expired AU2002333134B2 (en) | 2001-10-26 | 2002-10-22 | Montelukast granule formulation |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20030096840A1 (en) |
| EP (1) | EP1441701B1 (en) |
| JP (1) | JP4420671B2 (en) |
| KR (1) | KR101094084B1 (en) |
| CN (1) | CN100591329C (en) |
| AT (1) | ATE385781T1 (en) |
| AU (1) | AU2002333134B2 (en) |
| BR (1) | BR0213477A (en) |
| CA (1) | CA2463947C (en) |
| CY (1) | CY1107400T1 (en) |
| DE (1) | DE60225040T2 (en) |
| DK (1) | DK1441701T3 (en) |
| EC (1) | ECSP045082A (en) |
| EG (1) | EG24380A (en) |
| ES (1) | ES2298431T3 (en) |
| HR (1) | HRP20040367B1 (en) |
| HU (1) | HUP0401670A3 (en) |
| IL (1) | IL161299A0 (en) |
| MX (1) | MXPA04003856A (en) |
| MY (1) | MY148466A (en) |
| NO (1) | NO20042167L (en) |
| PE (1) | PE20030638A1 (en) |
| PT (1) | PT1441701E (en) |
| SI (1) | SI1441701T1 (en) |
| WO (1) | WO2003035036A1 (en) |
| ZA (1) | ZA200402584B (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040192660A1 (en) * | 2003-03-12 | 2004-09-30 | Mullally John P. | Protocol for improving vision |
| JP4991693B2 (en) * | 2005-03-16 | 2012-08-01 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Combinations of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases |
| CA2629904C (en) | 2005-11-28 | 2018-07-10 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
| EA021960B1 (en) | 2005-12-30 | 2015-10-30 | Крка, Товарна Здравил, Д.Д., Ново Место | Tablet containing a pharmaceutically acceptable salt of montelukast in amorphous form and process for preparation thereof |
| PL1818057T3 (en) * | 2006-02-09 | 2010-09-30 | Teva Pharma | Stable pharmaceutical formulations of montelukast sodium |
| CN103349659A (en) | 2006-09-26 | 2013-10-16 | 塔罗制药北美有限公司 | Liquid compositions and application |
| EP2262536A4 (en) * | 2008-03-26 | 2013-07-03 | Taro Pharmaceuticals North America Inc | Stabilizing lipid compositions for oral pharmaceutical agents |
| US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
| US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
| ES2596435T3 (en) | 2008-05-21 | 2017-01-09 | Ferring B.V. | Orodispersible desmopressin to increase the initial period of uninterrupted sleep due to nocturia |
| WO2009153305A2 (en) * | 2008-06-19 | 2009-12-23 | Sandoz Ag | Pharmaceutical compositions of montelukast sodium |
| EP2327424A4 (en) | 2008-08-18 | 2014-10-01 | Mitsubishi Shoji Foodtech Co Ltd | Novel excipient for mannitol tableting |
| EP2552418B1 (en) | 2010-03-29 | 2017-08-09 | Ferring B.V. | A fast dissolving pharmaceutical composition |
| JO3112B1 (en) | 2010-03-29 | 2017-09-20 | Ferring Bv | A fast dissolving pharmaceutical composition |
| FR2967066B1 (en) * | 2010-11-04 | 2013-06-14 | Ethypharm Sa | SUBLINGUAL USE OF NON-COMPRESSED MICROGRANULES |
| CN102085187B (en) * | 2011-01-27 | 2012-01-11 | 海南美大制药有限公司 | Montelukast sodium liposome solid preparation |
| RU2605929C2 (en) | 2011-07-26 | 2016-12-27 | Сан Фарма Адвансед Ресёрч Компани Лтд. | Quinoline and quinoxaline derivatives effective as cysteinyl-leukotriene antagonists |
| US9731018B2 (en) | 2011-09-16 | 2017-08-15 | Ferring B.V. | Fast dissolving pharmaceutical composition |
| WO2013077829A1 (en) | 2011-11-21 | 2013-05-30 | Mahmut Bilgic | Water-soluble pharmaceutical granules |
| EP3275466A1 (en) * | 2012-07-12 | 2018-01-31 | Ferring B.V. | Diclofenac formulations |
| WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
| US20140072628A1 (en) * | 2012-09-12 | 2014-03-13 | Glenmark Generics Ltd. | Stable pharmaceutical composition of saxagliptin |
| CN103520130B (en) * | 2013-10-15 | 2020-08-04 | 天垚医药科技发展（上海）有限公司 | Montelukast sodium time-selective controlled-release tablet and preparation method thereof |
| CN103520129B (en) * | 2013-10-15 | 2020-07-31 | 天垚医药科技发展（上海）有限公司 | Montelukast sodium pulse release preparation |
| CN103520136B (en) * | 2013-10-15 | 2020-07-31 | 天垚医药科技发展（上海）有限公司 | Montelukast sodium pulse capsule and preparation method thereof |
| CN104644564A (en) * | 2013-11-25 | 2015-05-27 | 天津汉瑞药业有限公司 | Stable granular preparation containing montelukast and preparation method thereof |
| CN103655497B (en) * | 2013-12-18 | 2018-05-29 | 北京华禧联合科技发展有限公司 | A kind of Montelukast Sodium oral disnitegration tablet and preparation method thereof |
| WO2015110394A1 (en) | 2014-01-22 | 2015-07-30 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier) |
| CN103720672B (en) * | 2014-01-26 | 2016-03-16 | 新疆特丰药业股份有限公司 | Montelukast sodium chewable tablet and direct powder compression preparation method thereof |
| CN104840427B (en) * | 2014-02-13 | 2017-09-29 | 长春海悦药业股份有限公司 | A kind of pharmaceutical composition containing Menglusitena |
| WO2016148455A2 (en) * | 2015-03-13 | 2016-09-22 | 경희대학교 산학협력단 | Method for improving montelukast bioavailability |
| JP6489435B2 (en) * | 2015-04-20 | 2019-03-27 | 高田製薬株式会社 | Montelukast sodium granule preparation |
| CN107595783A (en) * | 2017-06-01 | 2018-01-19 | 合肥远志医药科技开发有限公司 | A kind of Menglusitena particle and preparation method thereof |
| CN109833302A (en) * | 2017-11-29 | 2019-06-04 | 扬子江药业集团有限公司 | A kind of stable Montelukast sodium chewable tablet and preparation method thereof |
| CN110787139A (en) * | 2018-08-01 | 2020-02-14 | 北京万全德众医药生物技术有限公司 | Montelukast sodium pharmaceutical composition |
| CA3111275A1 (en) | 2018-09-06 | 2020-03-12 | Innopharmascreen Inc. | Methods and compositions for treatment of asthma or parkinson's disease |
| CN111110679A (en) * | 2018-10-31 | 2020-05-08 | 长春海悦药业股份有限公司 | Pharmaceutical composition containing montelukast sodium |
| CN111249238A (en) * | 2020-01-19 | 2020-06-09 | 安徽省先锋制药有限公司 | Preparation method of montelukast sodium granules |
| WO2022011210A1 (en) * | 2020-07-10 | 2022-01-13 | Sean Downing | Treatment for severe acute respiratory illness associated with coronavirus |
| CN111840233B (en) * | 2020-07-29 | 2022-05-06 | 浙江诺得药业有限公司 | Montelukast sodium solid dispersion, preparation method and application thereof |
| CN114224847B (en) * | 2021-12-07 | 2023-09-15 | 哈尔滨珍宝制药有限公司 | Preparation method of montelukast sodium particles |
| CN114425040A (en) * | 2022-02-24 | 2022-05-03 | 佑华医药科技有限公司 | Preparation method of montelukast sodium granules |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1561301A (en) * | 1976-01-02 | 1980-02-20 | Beecham Group Ltd | Orally administrable pharmaceutical composition |
| NZ230763A (en) * | 1988-09-27 | 1991-10-25 | Takeda Chemical Industries Ltd | Production of granules having a core by spraying the cores with a dispersion of hydroxypropylcellulose, optionally incorporating an active ingredient |
| FI894611A (en) * | 1988-09-30 | 1990-03-31 | May & Baker Ltd | GRANULAERA PHARMACEUTICAL PREPARATION. |
| DK0390435T3 (en) * | 1989-03-29 | 1994-03-21 | Takeda Chemical Industries Ltd | Mixture containing a compound of the vitamin B group, and preparation thereof |
| JP2800242B2 (en) | 1989-03-30 | 1998-09-21 | 大正製薬株式会社 | Manufacturing method of granules |
| US5565473A (en) * | 1990-10-12 | 1996-10-15 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
| JP2820829B2 (en) | 1991-03-07 | 1998-11-05 | 武田薬品工業株式会社 | Nucleated powder and production method thereof |
| JPH0967247A (en) | 1995-08-31 | 1997-03-11 | Taisho Pharmaceut Co Ltd | Production of medicinal preparation of uniformly fine particle |
| WO1997016173A1 (en) * | 1995-11-02 | 1997-05-09 | Merck Frosst Canada Inc. | New technology for wet granulation |
| US5869098A (en) * | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
| HUP0101369A3 (en) | 1997-12-23 | 2002-11-28 | Schering Corp | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine |
| US6224907B1 (en) * | 1998-03-06 | 2001-05-01 | Alza Corporation | Anti-asthma therapy |
| US6103735A (en) * | 1998-10-09 | 2000-08-15 | Schering Corporation | Composition and method for treating allergic diseases |
| US6221880B1 (en) * | 1998-10-09 | 2001-04-24 | Schering Corporation | Composition and method for treating allergic diseases |
| AT413647B (en) | 1998-11-26 | 2006-04-15 | Sandoz Ag | USE OF A COPOLYMERISATE OF 1-VINYL-2-PYRROLIDONE AND VINYL ACETATE FOR THE PREPARATION OF CEFUROXIMAXETIL-SUBJECTED TABLETS |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6491949B2 (en) * | 2000-01-14 | 2002-12-10 | Osmotica Corp. | Osmotic device within an osmotic device |
| US20030031720A1 (en) * | 2000-02-24 | 2003-02-13 | Tobias Laich | Method for producing pharmaceutical dosage forms |
| US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
-
2002
- 2002-10-17 MY MYPI20023875A patent/MY148466A/en unknown
- 2002-10-22 DE DE60225040T patent/DE60225040T2/en not_active Expired - Lifetime
- 2002-10-22 MX MXPA04003856A patent/MXPA04003856A/en active IP Right Grant
- 2002-10-22 WO PCT/CA2002/001604 patent/WO2003035036A1/en active IP Right Grant
- 2002-10-22 BR BR0213477-2A patent/BR0213477A/en active Pending
- 2002-10-22 DK DK02801836T patent/DK1441701T3/en active
- 2002-10-22 JP JP2003537603A patent/JP4420671B2/en not_active Expired - Lifetime
- 2002-10-22 HU HU0401670A patent/HUP0401670A3/en unknown
- 2002-10-22 CN CN02821212A patent/CN100591329C/en not_active Expired - Lifetime
- 2002-10-22 EP EP02801836A patent/EP1441701B1/en not_active Revoked
- 2002-10-22 SI SI200230670T patent/SI1441701T1/en unknown
- 2002-10-22 CA CA002463947A patent/CA2463947C/en not_active Expired - Lifetime
- 2002-10-22 PT PT02801836T patent/PT1441701E/en unknown
- 2002-10-22 KR KR1020047006095A patent/KR101094084B1/en active IP Right Review Request
- 2002-10-22 ES ES02801836T patent/ES2298431T3/en not_active Expired - Lifetime
- 2002-10-22 AU AU2002333134A patent/AU2002333134B2/en not_active Expired
- 2002-10-22 IL IL16129902A patent/IL161299A0/en unknown
- 2002-10-22 AT AT02801836T patent/ATE385781T1/en active
- 2002-10-23 EG EG2002101164A patent/EG24380A/en active
- 2002-10-24 US US10/279,595 patent/US20030096840A1/en not_active Abandoned
- 2002-10-24 PE PE2002001047A patent/PE20030638A1/en active IP Right Grant
-
2004
- 2004-04-01 ZA ZA2004/02584A patent/ZA200402584B/en unknown
- 2004-04-23 HR HRP20040367AA patent/HRP20040367B1/en not_active IP Right Cessation
- 2004-04-23 EC EC2004005082A patent/ECSP045082A/en unknown
- 2004-05-25 NO NO20042167A patent/NO20042167L/en not_active Application Discontinuation
-
2008
- 2008-02-07 US US12/069,124 patent/US8007830B2/en not_active Expired - Fee Related
- 2008-04-17 CY CY20081100434T patent/CY1107400T1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2463947C (en) | Montelukast granule formulation | |
| AU2002333134A1 (en) | Montelukast granule formulation | |
| US6214386B1 (en) | Prompt-release oral pharmaceutical compositions for extemporaneous suspensions | |
| EP2560613B1 (en) | Fexofenadine-based composition and preparation process therefor | |
| TWI228414B (en) | Pharmaceutical composition comprising carvedilol and hydrochlorothiazide, solid dosage form comprising it, and process for the production of the same | |
| JP2005527508A (en) | Rapid melting multiparticulate formulation for oral delivery | |
| US20100183730A1 (en) | High dose composition of ursodeoxycholic acid | |
| CN108159019A (en) | Fexofenadine microcapsules and the composition containing fexofenadine microcapsules | |
| EP1708683A1 (en) | Cefuroxime axetil granule and process for the preparation thereof | |
| WO2009153305A2 (en) | Pharmaceutical compositions of montelukast sodium | |
| EP0862421B1 (en) | Prompt-release pharmaceutical compositions | |
| JP5327682B2 (en) | Pharmaceutical composition used as laxative | |
| WO2010119851A1 (en) | Orally disintegrating tablet | |
| US9333170B2 (en) | Polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof | |
| JPH069376A (en) | Coated core pharmaceutical preparation | |
| TWI326601B (en) | Granule formulation | |
| KR20240004942A (en) | Taste-masked compositions of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamidehemisuccinate and compositions thereof Orally disintegrating tablet comprising | |
| MX2012012140A (en) | Fexofenadine-based composition and preparation process therefor. |